We are live on ! Find out more
BLUE

bluebird bio

Delisted

BLUE was delisted on the 30th of May, 2025.

243 hedge funds and large institutions have $6.9B invested in bluebird bio in 2017 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 105 increasing their positions, 61 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 61

48% more call options, than puts

Call options by funds: $163M | Put options by funds: $110M

33% more capital invested

Capital invested by funds: $5.17B → $6.9B (+$1.72B)

15% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 39

1% more funds holding

Funds holding: 241243 (+2)

0% more ownership

Funds ownership: 8.51%8.51% (+0%)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
243
Holders Change
+2
Holders Change %
+0.83%
% of All Funds
6.06%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
45
Increased
105
Reduced
61
Closed
39
Calls
$163M
Puts
$110M
Net Calls
+$52.9M
Net Calls Change
-$6.76M

BLUE Hedge Fund Activity: Q3 2017 in Review

243 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2017, worth a combined $6.9B — up 33% from $5.17B a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new BLUE positions and 39 closed out — a net gain of 6 holders — while 105 added to existing stakes and 61 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $38.4M. The largest seller was Victory Capital Management, cutting an estimated $24.2M.

  • 243 institutional investors held bluebird bio (BLUE) as of Q3 2017, up from 241 in Q2 2017.
  • Funds reported $6.9B of bluebird bio stock for Q3 2017, up 33% quarter-over-quarter.
  • 45 funds opened new bluebird bio positions in Q3 2017 and 39 closed out, a net change of +6 holders.
  • The largest bluebird bio buyer in Q3 2017 was Wellington Management Group, an estimated $38.4M added.
  • The largest bluebird bio seller in Q3 2017 was Victory Capital Management, an estimated $24.2M sold.

Based on aggregated 13F filings for Q3 2017.